Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 12 Parkinson's papers of 668 | 0.66 |
| pathways Reactome | 4 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 8381
Sealed predictions
- FXN in dopamine neurons, braak+0.11 (p 0.770) → +0.63 (p 0.068)receipt 8388
Swarm cases
receipt 8388: FXN in dopamine neurons, braak
- power
- full sample +0.39 (p 0.111, n 18), 95% CI -0.10 to +0.72. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.39 (p 0.111, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.32 (p 0.194, n 18). could be the mix.
- skeptic
- leave-one-out range +0.31 to +0.57, sign flips 0; without severely affected donors +0.39 (p 0.111, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FXN in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts